← boardnext 2027-09-20next 2030-04-01
NVO
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companydistress 2/10 · well-funded / low risk$48.73+1%today-32% from 52w high
Metabolic / Obesity 1
Lead: Sickle Cell Disease · target GLP-1 · est. market ~$5B (approx, global)
Revenue
$96823M
Liquidity
$23867M
Runway
—
Shares 1y
—
Price & events
-18.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.1%
1D
-5.3%
1W
+2.8%
1M
+26.5%
3M
-18.9%
6M
-27.0%
1Y
-60.9%
2Y
+19.6%
5Y
+54.1%
All
Overview
- Volume
- 1.57M
- 52 Week Range
- $35.29 – $71.70
- Float Shares
- 3.18B
- Short %
- 0.88%
- % Held by Insiders
- 0.01%
- % Held by Institutions
- 9.91%
- RVOL
- 0.15x
- Beta
- 0.36
Pipeline stages · 3 programs
Etavopivat
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
DCR-PHXC
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Oral semaglutideGLP-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-09-20 Estimated 50% readout ~2027-11-04 | Phase 2 | Etavopivat, Hydroxyurea | Sickle Cell Disease | — | recruiting |
| 2028-02-23 Estimated 50% readout ~2028-04-08 | Phase 2 | Etavopivat | Sickle Cell Disease | — | recruiting |
| 2030-04-01 Estimated 50% readout ~2030-06-15 | Phase 3 | DCR-PHXC | Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease, Primary Hyperoxaluria Type 3 (PH3) | — | active not recruiting |
| 2031-12-30 Estimated 50% readout ~2032-02-13 | Phase 2 | DCR-PHXC | Primary Hyperoxaluria Type 1, End Stage Renal Disease | — | recruiting |
| 2026-06-29 | Phase 3 | Oral semaglutide | Type 2 Diabetes | — | active not recruiting |
Catalyst news & presentations · 1
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $47 (-3% upside) · 12 analysts
- 2026-03-02Goldman SachsBuy → Neutral
- 2026-02-24JP MorganOverweight → Neutral
- 2026-01-09CICCOutperform
- 2025-12-08Argus ResearchBuy → Hold
- 2025-11-28Goldman SachsBuy
- 2025-11-25BMO CapitalMarket Perform
Competitors — GLP-1
Recent news
- 2026-07-22Novo Nordisk stock trades near record levels as Wegovy momentum supports earnings outlook - Ad-hoc-news.de
- 2026-07-21Novo Nordisk stock trades near record levels as obesity drug growth reshapes earnings profile - Ad-hoc-news.de
- 2026-07-20Update: Novo Nordisk's Wegovy Approved in India for Fatty Liver Disease Treatment - Moomoo
- 2026-07-20Novo Nordisk A/S - share repurchase programme - The Manila Times
- 2026-07-16Novo's Wegovy pill cleared for weight loss in EU - pharmaphorum
- 2026-07-15Wegovy Pill in Europe - Novo Nordisk Expands Franchise With First European Approval for Oral Weight Loss Drug - Benzinga
- 2026-07-13Novo Nordisk A/S - Share Repurchase Programme - 富途牛牛
- 2026-07-10NONOF SEC Filings - Novo-Nordisk A S 10-K, 10-Q, 8-K Forms - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.